Investor Relations
Corporate Profile
MELA Sciences is a medical technology company dedicated to designing and developing innovative software-driven technology for the clinical early detection and prevention of skin cancer. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature.
Download Documentation CLICK HERE for MELA Sciences Conference Call Slides June 23 2015

For the latest investor presentation please contact Andrew McDonald at

Stock Quote
Last Trade: $1.20*
Change (%): 0.01 (0.84%)
Volume: 2,751
*minimum 20 min. delay

Webcast - Launch
Q3 2015 MELA Sciences Earnings Conference Call
16:30:00 12 Nov 2015 ET

Webcast - Launch
Q2 2015 MELA Sciences Earnings Conference Call
16:30:00 13 Aug 2015 ET

Webcast - Launch
MELA Sciences at OneMedForum
14:00:00 13 Jan 2015 PT

Investor Relations Contact Information

Andrew McDonald
LifeSci Advisors, LLC
250 W. 55th Street, #16B
New York, NY 10019

MELA Sciences RSS

Subscribe to MELA Science’s RSS (Really Simple Syndication) feeds to get information delivered directly to your desktop!

Clicking on an RSS link below will provide you with raw XML data of our content. If you do not have a compatible reader installed, you will see XML code in your browser - to view our content, paste the feed address into an RSS reader, or use a browser which supports RSS feeds. See below for additional information on RSS.

MELA Sciences RSS Feeds

Additional Information About RSS
Really Simple Syndication (RSS) is an XML-based format for distributing and aggregating Web content (such as news headlines). Using RSS, web content providers can easily create and disseminate news headlines and URLs. To find more information about common RSS Readers, enter the term “RSS Reader” into an internet search engine.